Healio sat down with Stockfelt to discuss the limitations of rituximab, the optimal SLE populations for B-cell depletion and the future of personalized medicine in the disease. Healio: Why did you ...

After B-cell depletion with rituximab, repletion of the peripheral B-cell compartment in patients with rheumatoid arthritis (RA) recapitulates events during B-cell ontogeny. In this context ...

Rituximab, a CD20-specific monoclonal antibody ... Now, Tedder and colleagues help to resolve this issue by showing that B-cell depletion with a CD20-specific antibody has opposing effects on ...

Variability in rituximab pharmacokinetics has been well documented in B-cell malignancies and RA. Early studies in NHL employing the same treatment regimen found remarkable variability in serum ...

Data taken from [12]. Despite recent advances in the treatment of B-cell malignancies with rituximab, patients often relapse and need alternative treatment options, particularly those with prior ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

Patients living with HIV (PLWH) were eligible if their CD4 + T-cell count was ... positive for hepatitis B sAg or detectable hepatitis B viremia were eligible, provided that they initiated antiviral ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...

Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward developing “new and improved” B-cell depleting agents for patients with the disease ...